Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 and Adenovirus 5 with Chemo in Recurrent Cervical Cancer
NCT06455046Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, Oncorine in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Started Oct 2023; status: recruiting.
02
Drugs
cadonilimabOncorine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06455046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455046.